Streetbeat News

Analyst Ratings

CI

The article provides an analysis of Cigna (NYSE:CI) based on insights from 11 analysts over the past three months. The analysts' ratings range from bullish to somewhat bullish, with an average 12-month price target of $405.36. Cigna's financial performance is strong, with significant revenue growth, high net margins, and effective debt management.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:00 pm

SBRA

Wells Fargo analyst John Kilichowski has assumed coverage of Sabra Health Care REIT with an Overweight rating and increased the price target to $20.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:58 pm

CVS

Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health and maintained a $62 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:55 pm

NHI

Wells Fargo analyst John Kilichowski has assumed coverage of National Health Investors (NYSE:NHI) with an Equal-Weight rating and has raised the price target to $86.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:55 pm

CNC

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Centene (NYSE:CNC) and maintained a $90 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:53 pm

CI

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Cigna (NYSE:CI) and maintained a $400 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:51 pm

ACHC

Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on Acadia Healthcare Co (NASDAQ:ACHC) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:49 pm

MGY

Wells Fargo has downgraded Magnolia Oil & Gas from Equal-Weight to Underweight and reduced its price target from $26 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:44 pm

CTRE

Wells Fargo has upgraded CareTrust REIT (NYSE:CTRE) from Equal-Weight to Overweight and increased its price target from $28 to $34.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:39 pm

IGMS

Wedbush analyst Robert Driscoll maintains an Outperform rating on IGM Biosciences but lowers the price target from $25 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:38 pm